Responses of cerebral arterioles to kainate.

BACKGROUND AND PURPOSE: Neurons release nitric oxide in response to glutamate. Glutamate acts via activation of different receptor subtypes, including N-methyl-D-aspartate and kainate receptors. This study examined the hypothesis that kainate produces dilatation of cerebral arterioles that is dependent on the formation of nitric oxide. METHODS: Diameters of cerebral arterioles were measured by means of a closed cranial window in anesthetized rabbits. Kainate, quisqualate, acetylcholine, and NG-nitro-L-arginine (L-NNA, an inhibitor of nitric oxide synthase) were applied locally in the cranial window. We also examined whether kainate elicited direct vascular effects by the use of isolated cerebral arteries in vitro. RESULTS: Under control conditions, topical kainate (100 mumol/L) increased the diameter of arterioles by 20 +/- 5% (mean +/- SE), 27 +/- 7%, and 31 +/- 7% at 3, 5, and 9 minutes of application, respectively. After topical application of L-NNA (300 mumol/L), kainate dilated cerebral arterioles by 8 +/- 4%, 9 +/- 5%, and 8 +/- 6% at 3, 5, and 9 minutes, respectively (P < .05 versus the control response). In contrast, quisqualate (100 and 300 mumol/L) did not alter the diameter of cerebral arterioles. In rings of the middle cerebral artery studied in vitro, kainate had no effect on vascular tone, which suggests that cerebral vessels lack receptors for kainate. Thus, cerebral vasodilator effects of kainate do not appear to be due to the direct effect of the excitatory amino acid on cerebral vessels. CONCLUSIONS: These findings suggest that kainate produces dilatation of cerebral arterioles in vivo that is mediated by release of nitric oxide from an extravascular source.

Cerebral vasodilation during hypercapnia. Role of glibenclamide-sensitive potassium channels and nitric oxide.

BACKGROUND AND PURPOSE: The purpose of these experiments was to examine mechanisms by which hypercapnia produces vasodilatation in brain. We examined the hypothesis that dilatation of cerebral arterioles during hypercapnia is dependent on activation of ATP-sensitive potassium channels and formation of nitric oxide. METHODS: Diameters of cerebral arterioles were measured using a closed cranial window in anesthetized rabbits. Changes in diameter of arterioles were measured in response to topical application of acetylcholine and sodium nitroprusside and during two levels of systemic hypercapnia. RESULTS: Increasing arterial PCO2 from 32 +/- 1 mm Hg (mean +/- SE) to 54 +/- 1 and 66 +/- 1 mm Hg dilated cerebral arterioles by 25 +/- 3% and 38 +/- 5%, respectively, from a control diameter of 93 +/- 3 microns. The response to the low level of hypercapnia was attenuated (25 +/- 3% versus 16 +/- 4%, P < .05) by glibenclamide (1 mumol/L), an inhibitor of ATP-sensitive potassium channels. Vasodilatation in response to the high level of hypercapnia was not affected by glibenclamide. Increases in arteriolar diameter in response to sodium nitroprusside were not inhibited by glibenclamide. NG-nitro-L-arginine (300 mumol/L), an inhibitor of nitric oxide synthase, completely inhibited dilatation of cerebral arterioles in response to the low level of hypercapnia and inhibited vasodilatation during the high level of hypercapnia by 66%. CONCLUSIONS: Thus, activation of glibenclamide-sensitive potassium channels may contribute to dilatation of cerebral arterioles during hypercapnia. Cerebral vasodilatation during hypercapnia is dependent in large part on production of nitric oxide.

Dilatation of cerebral arterioles in response to N-methyl-D-aspartate: role of CGRP and acetylcholine.

The purpose of these experiments was to examine mechanisms by which N-methyl-D-aspartate (NMDA) produces nitric oxide-dependent vasodilatation in brain. Some nitrovasodilators appear to dilate cerebral arterioles, in part, by release of calcitonin gene-related peptide (CGRP) from trigeminal fibers. The first goal of this study was to examine the hypothesis that dilatation of cerebral arterioles in response to NMDA is mediated by activation of receptors for CGRP. Diameters of cerebral arterioles were measured using a closed cranial window in anesthetized rabbits. Topical CGRP (1 and 10 nM) dilated cerebral arterioles by 30 +/- 9 (mean +/- S.E.M.) and 72 +/- 9%, respectively, from a control diameter of 94 +/- 7 microns. This response was inhibited almost completely by the CGRP antagonist CGRP(8-37) (0.5 microM). NMDA (100 and 300 microM) dilated cerebral arterioles by 14 +/- 5 and 38 +/- 7% in the absence and 20 +/- 5% and 30 +/- 6% in the presence, respectively, of CGRP(8-37). Neurons may release acetylcholine in response to activation with NMDA. The second goal of the present study was to examine the hypothesis that dilatation of cerebral arterioles in response to NMDA is mediated by acetylcholine. Topical atropine (2 micrograms/ml) completely inhibited dilatation of cerebral arterioles in response to acetylcholine, but had no effect on vasodilatation in response to NMDA. Thus, vasodilatation of cerebral arterioles in response to NMDA does not appear to be dependent on activation of receptors for CGRP or acetylcholine.

Nitric oxide contributes to dilatation of cerebral arterioles during seizures.

Endogenous release of excitatory amino acids during seizures produces marked increases in neuronal activity and guanosine 3',5'-cyclic monophosphate levels in brain tissue, which are mediated by nitric oxide (NO). We tested the hypothesis that dilatation of the cerebral microcirculation during seizures is mediated by NO. Diameters of cerebral arterioles were measured using a closed cranial window in anesthetized rabbits. Three, five, nine, and eleven minutes after the onset of pentylenetetrazole-induced seizure (which releases endogenous excitatory amino acids), arteriolar diameter increased by 42 +/- 6, 30 +/- 3, 20 +/- 2, and 16 +/- 2% (means +/- SE), respectively, from a control diameter of 86 +/- 6 microns. Arterial pressure was maintained at control levels during seizures. In the presence of NG-nitro-L-arginine (L-NNA, 300 microM), an inhibitor of NO synthase, vasodilatation during seizures was not affected at 3 min (40 +/- 8%) but was significantly reduced at 5, 9, and 11 min (17 +/- 5, 6 +/- 3, and 1 +/- 3%, respectively, P < 0.05 vs. control). Vasodilatation in response to topical application of acetylcholine (1 microM) was also inhibited by L-NNA (33 +/- 5 vs. 3 +/- 2%, P < 0.05). Dilatation of cerebral arterioles in response to nitroprusside (1 and 10 microM) was not inhibited by L-NNA. Thus sustained, but not initial, dilatation of cerebral arterioles during seizures appears to be mediated in part by NO.

Nitric oxide mediates vasodilatation in response to activation of N-methyl-D-aspartate receptors in brain.

Neurons release nitric oxide (NO) in response to activation of receptors for the excitatory amino acid N-methyl-D-aspartate (NMDA). We examined the hypothesis that activation of receptors for NMDA produces dilatation of the cerebral microcirculation that is mediated by NO. Diameters of cerebral arterioles were measured using a closed cranial window in anesthetized rabbits. Under control conditions, topical NMDA produced concentration-related dilatation of pial arterioles. Dilatation in response to NMDA was inhibited selectively by MK-801 (an NMDA receptor antagonist) and tetrodotoxin, suggesting that responses to NMDA were receptor mediated and dependent on neuronal activation. Increases in arteriolar diameter in response to NMDA were not affected by L-arginine but were inhibited by NG-nitro-L-arginine, suggesting that the vasodilatation was mediated by NO. Dilatation of cerebral arterioles in response to NMDA was not inhibited by indomethacin, suggesting that cyclooxygenase products do not mediate the response. Using isolated cerebral arteries, we also examined whether NMDA elicited direct cerebral vascular effects. In intact arteries studied in vitro, NMDA had no effect on vascular tone, suggesting that cerebral arteries lack receptors for NMDA. These findings suggest that NO generated in response to activation of receptors for NMDA in vivo is neuronally derived and not due to a direct vascular effect. Thus, NO may mediate increases in local blood flow during increases in neuronal activity in response to excitatory amino acids.

Acetylcholine-induced vasodilatation in rabbit hindlimb in vivo is not inhibited by analogues of L-arginine.

Nitric oxide (NO) or related nitroso compounds are an endothelium-derived relaxing factor (EDRF), originating from metabolism of L-arginine, L-Arginine analogues with chemically altered guanidino moity are potent and specific inhibitors of EDRF(NO) release. We evaluated effects of two L-arginine analogues, NG-monomethyl-L-arginine (L-NMMA, 100 microM) and N omega-nitro-L-arginine (L-NARG, 30 microM), on acetylcholine-, substance P-, and nitroglycerin-induced relaxation in the blood-perfused rabbit hindlimb in vivo and femoral arteries in vitro. L-NMMA and L-NARG selectively inhibited the vasodilator response to acetylcholine in rabbit femoral arteries in vitro, whereas endothelium-independent response to nitroprusside increased. L-NMMA (1.6 mg/min ia) in the blood-perfused rabbit hindlimb in vivo increased vascular resistance in the hindlimb by 23 +/- 3% (means +/- SE; n = 10) but did not inhibit the vasodilator responses to acetylcholine or substance P. L-NARG (10 mg/kg iv) increased systemic blood pressure by 26 +/- 3% (n = 7) and vascular hindlimb resistance by 22 +/- 9% (n = 8), and blood flow to hindlimb musculature, measured with microspheres, decreased by 46 +/- 5% (n = 6). Pretreatment with L-NARG, however, did not impair vasodilator responses to acetylcholine and substance P. These findings are consistent with the view that basal tone in resistance vessels in the rabbit hindlimb may be mediated by nitroso compounds, whereas agonist-stimulated vasodilation may be mediated by other mechanisms that do not involve the NO-synthesizing enzyme.

Atherosclerosis potentiates constrictor responses of cerebral and ocular blood vessels to thromboxane in monkeys.

The goal of our study was to examine the effects of infusion of serotonin and the thromboxane A2 analogue U46619 into one carotid artery to stimulate their release from platelets during aggregation. We measured blood flow to the brain and eye using microspheres and cerebral microvascular pressure in the pial arteries of normal and atherosclerotic cynomolgus monkeys. Unilateral intracarotid infusion of 10-30 micrograms/min serotonin did not affect cerebral blood flow in normal or atherosclerotic monkeys; serotonin did not alter blood flow to the eye in normal monkeys but decreased flow to the retina and choroid in atherosclerotic monkeys by 39 +/- 11% and 44 +/- 10% (mean +/- SEM), respectively. Infusion of 30 ng/min U46619 did not alter cerebral blood flow but increased the pressure gradient from the aorta to the pial artery, which is an index of large-artery resistance, in atherosclerotic monkeys. U46619 had no effect on blood flow to the eye in normal monkeys but decreased blood flow to the retina and choroid by 71 +/- 14% and 53 +/- 13%, respectively, in atherosclerotic monkeys. Thus, atherosclerosis potentiates the constrictor responses of large cerebral arteries to thromboxane and the responses of blood vessels of the eye to thromboxane and serotonin.